OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025

About this update from Ose Immunotherapeutics Sa

[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance Publication of Circular for Combined Annual General Meeting of September 30, 2025","length":180,"tagName":"p"},{"type":"text","content":"Nantes, September 9, 2025, 8:30 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the release of preparatory documents for its Combined Annual General Meeting (AGM) scheduled for September 30, 2025, at 10 a.m. at the Drawing House Hotel - 21, rue Vercingétorix - 75014 Paris.","length":305,"tagName":"p"},{"type":"text","content":"The Board urges shareholders to vote in favor of a strategy and governance model that has delivered strong clinical results and significant value for shareholders. As part of its commitment to balanced governance, the Board has endorsed the appointment of Jonathan Cool and Pascale Briand, two candidates proposed by the minority shareholder group, whose nominations are presented as resolutions approved by the Board.","length":418,"tagName":"p"},{"type":"text","content":"A Defining Moment for OSE","length":25,"tagName":"p"},{"type":"text","content":"Under current leadership, OSE Immunotherapeutics achieved solid financial and clinical performance in 2024, driven by a balanced pipeline and disciplined financing. At this AGM, shareholders face a clear choice:","length":211,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Support a value-driving strategy and balanced governance, or","length":60,"tagName":"p"}]},{"val":[{"type":"text","content":"Endorse an alternative proposal from a minority group, which risks reversing progress and jeopardizing shareholder value.","length":121,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":181,"olType":false},{"type":"text","content":"Didier Hoch, Chai...

More updates from Ose Immunotherapeutics Sa